Cipla FY26: Profit Falls 27% As Revenue Inches Up; Acquisition Complete

Cipla announced its financial results for the fiscal year ending March 31, 2026. Consolidated revenue saw a modest increase to ₹28,162.59 crore from ₹27,547.62 crore in the prior year. However, consolidated Profit After Tax (PAT) experienced a significant 27% drop, falling to ₹3,861.74 crore from ₹5,269.20 crore in FY25.

Key Financials and Updates

The company's Board of Directors approved the audited financial results for the fiscal year ending March 31, 2026. A final dividend of ₹13 per equity share was recommended for FY26. The acquisition of a 100% stake in Inzpera Healthscience Limited was finalized. An exceptional charge of ₹275.91 crore was recognized relating to new labour legislation. Cipla has also reassessed its operating segments, now classifying itself as operating in a single segment: Pharmaceutical and related products. The statutory auditors provided an unqualified opinion on the financial results.

What the Results Mean

The sharp decline in profit, even with revenue growth, suggests possible margin pressures or higher operating expenses. Management recommended a ₹13 per share dividend, pending shareholder approval, signaling confidence in future prospects despite the current profit dip. The finalized acquisition of Inzpera Healthscience marks a strategic expansion and aims to drive future growth. Operating as a single pharmaceutical segment may simplify reporting and enhance operational focus.

Recent Strategic Moves

This latest acquisition follows Cipla's pattern of inorganic growth. Previously, the company acquired Amneal Pharmaceuticals of India in August 2022 for ₹870 crore, demonstrating a consistent strategy for portfolio expansion.

Impact and Future Outlook

The final dividend, if approved by shareholders at the Annual General Meeting (AGM), will be distributed shortly after. The Inzpera Healthscience acquisition is expected to create new opportunities for business growth and market penetration. The company must continue to monitor ongoing litigation and associate impairment as factors influencing financial stability.

Risks and Challenges

Ongoing litigation related to NPPA demand notices for alleged overcharges dating back to 1998 continues. Cipla has made partial payments totaling ₹175.08 crore and ₹27.07 crore. An impairment loss of ₹42.02 crore was recorded for associates, attributed to changes in business conditions and market dynamics. The pressure on profit margins observed in FY26 is a key risk that could affect future earnings.

Market Context: Peer Performance

Cipla's FY26 performance contrasts with many peers like Sun Pharma and Dr. Reddy's Laboratories, which often report stable or growing profits despite operating diverse global businesses. Cipla's revenue grew modestly, but its profit declined sharply. Other pharmaceutical players, including Zydus Lifesciences, also navigate complex regulatory environments and evolving market dynamics.

Financial Performance Snapshot

For the full year FY26, consolidated revenue from operations reached ₹28,162.59 crore, up from ₹27,547.62 crore in FY25. Consolidated Profit After Tax, however, fell to ₹3,861.74 crore from ₹5,269.20 crore in the previous year. On a standalone basis, revenue from operations was ₹18,979.95 crore in FY26, a slight decrease from ₹19,044.85 crore in FY25. Standalone Profit After Tax also declined, reporting ₹3,515.18 crore in FY26 compared to ₹5,157.65 crore in FY25.

What to Watch For

Shareholders will vote on the recommended final dividend at the upcoming Annual General Meeting (AGM). The company plans to distribute the approved final dividend within 30 days of the AGM. Investors will track updates on the integration and performance of the newly acquired Inzpera Healthscience. Management's commentary on the drivers of the profit decline and its outlook for FY27 will be crucial. The resolution status and potential outcomes of the ongoing NPPA litigation will be closely monitored.